CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
由 hospitalist 主导的门诊操作服务弥合肿瘤诊疗中的缺口
英文原题：Outpatient hospitalist-run procedure service bridges the gap in oncology care.
查看英文原题
Outpatient hospitalist-run procedure service bridges the gap in oncology care.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
由住院医师主导的操作团队可加快住院患者接受操作的进程。然而，本机构门诊介入放射科（IR）的等待时间较长。因此，本研究比较接受CAR-T 细胞疗法采集的门诊患者，通过操作团队或 IR 放置临时血液透析导管（THDC）的安全性和等待时间。研究回顾了 2019 年 8 月至 2022 年 11 月所有接受门诊 THDC 放置以进行 CAR-T 治疗的患者病历。研究期间，75 条中心静脉导管由操作服务团队放置，只有 7 条由 IR 放置。从 CAR-T 知情同意到实施操作的平均等待时间，操作服务团队为 8.9 天，IR 为 14.7 天。30 天轻微并发症发生率较低，操作团队组为 2.7%，IR 组为 0%；两组均未出现严重并发症。
展开英文摘要原文
Hospitalist-run procedure teams enable expedited care in the inpatient setting.
However, wait times for outpatient interventional radiology (IR) are long at our institution.
Our study thus aims to compare the safety and wait times between procedural teams and IR placement of outpatient temporary hemodialysis catheters (THDC) for patients undergoing Chimeric antigen receptor T-cell (CAR-T) therapy apheresis. A retrospective chart review was conducted on all patients receiving outpatient THDC for CAR-T therapy from August 2019 until November 2022.
During our study period, only 7 of the central lines were placed by IR, while 75 were placed by the procedure service. The average wait time from CAR-T consenting to procedure was 8. 9 days for the procedure service and 14. 7 days for IR. The 30 day minor complication rate was low - 2. 7% in the procedure group, and 0% in the IR group. No major complications were noted in either group.
论文信息
- 作者
- Ghanem G、Tsai HHC、Durant C、Feigenbaum GS、Glaeser AM
- 单位
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: gghanem@ucla.edu.United States
- 期刊
- Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2024 Jun
- 原文标识
- PubMed 38658295 · DOI 10.1016/j.transci.2024.103936